NCT04708418 2026-03-18
A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC